Schering-Plough
This article was originally published in The Tan Sheet
Executive Summary
Sun care sales leaped 28% to $92 mil. in second quarter on initial sell-in of Coppertone Endless Summer sunless tanning lotion, firm tells analysts June 25. Foot care revenues fell 3% to $97 mil. "due to increased competition"; OTC sales dropped 5% to $42 mil. Company previously predicted OTC business shortfall due to GMP problems (1"The Tan Sheet" Feb. 19, p. 7). CEO Richard Kogan says Schering has "made progress toward resolving these manufacturing issues." Net sales and income both were flat at $2.63 bil. and $634 mil., respectively
You may also be interested in...
Schering-Plough Reduced OTC Sales Forecast Due To GMP Problems
Certain OTC products manufactured by Schering-Plough will see reduced sales due to a problematic manufacturing process and control issues cited by FDA, the company said.
Supplement GMP Warning Letters Make Modest Debut In 2010
Finalization of a settlement between the Federal Trade Commission and Rexall Sundown regarding unsupported cellulite treatment claims for the firm's Cellasene dietary supplement hinges upon approval of two related class action settlements pending in California and Florida, according to FTC
In Brief
Combe sells most of its OTC brands